April 20, 2024

• 

[THE INVESTOR] Hanmi Pharmaceutical will meet market expectations in the third quarter and expectations for its R&D results will rise, said NH Investment and Securities on Oct. 10. 

The securities firm raised the target price to 530,000 won (US$465.12) from 480,000 won and maintained a “buy” recommendation. 

Results from investigator trials for its non-small cell lung cancer drug will be released in the fourth quarter and those from the phase 3 clinical trials for Rolontis, a drug candidate for chemotherapy-induced neutropenia it has exported to Spectrum, will be out in the first quarter next year, explained analyst Koo Wan-seong. 

The novel drug candidate is worth 533.7 billion won, according to the analyst who estimated the total market value of the firm at 5.93 trillion won. A total of three pre-clinical products in the pipeline will initiate clinical trials by the first quarter of 2018, Koo added. 

Its third-quarter revenue will reach 215.7 billion won with operating profit of 20.4 billion won, and its product portfolio is improving as it has launched six new incrementally modified drugs this year, noted the analyst. 

By Hwang You-mee (glamazon@heraldcorp.com)